| CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment Y Jin, Z Desta, V Stearns, B Ward, H Ho, KH Lee, T Skaar, AM Storniolo, ... Journal of the National Cancer Institute 97 (1), 30-39, 2005 | 1064 | 2005 |
| Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment S Borges, Z Desta, L Li, TC Skaar, BA Ward, A Nguyen, Y Jin, ... Clinical Pharmacology & Therapeutics 80 (1), 61-74, 2006 | 515 | 2006 |
| Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate R Arora, MO Koch, JN Eble, TM Ulbright, L Li, L Cheng Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 319 | 2004 |
| Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer NL Henry, F Azzouz, Z Desta, L Li, AT Nguyen, S Lemler, J Hayden, ... Journal of Clinical Oncology 30 (9), 936, 2012 | 265 | 2012 |
| Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant M Fan, PS Yan, C Hartman-Frey, L Chen, H Paik, SL Oyer, JD Salisbury, ... Cancer research 66 (24), 11954-11966, 2006 | 252 | 2006 |
| Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro Z Desta, T Saussele, B Ward, J Blievernicht, L Li, K Klein, DA Flockhart, ... Future Medicine Ltd 8 (6), 547-558, 2007 | 222 | 2007 |
| Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors NL Henry, JT Giles, D Ang, M Mohan, D Dadabhoy, J Robarge, J Hayden, ... Breast cancer research and treatment 111 (2), 365-372, 2008 | 201 | 2008 |
| Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate C Sweeney, L Li, R Shanmugam, P Bhat-Nakshatri, V Jayaprakasan, ... Clinical Cancer Research 10 (16), 5501-5507, 2004 | 201 | 2004 |
| Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans Z Wang, SD Hall, JF Maya, L Li, A Asghar, JC Gorski British journal of clinical pharmacology 55 (1), 77-85, 2003 | 191 | 2003 |
| A community computational challenge to predict the activity of pairs of compounds M Bansal, J Yang, C Karan, MP Menden, JC Costello, H Tang, G Xiao, ... Nature biotechnology 32 (12), 1213-1222, 2014 | 189 | 2014 |
| Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells YC Lim, L Li, Z Desta, Q Zhao, JM Rae, DA Flockhart, TC Skaar Journal of Pharmacology and Experimental Therapeutics 318 (2), 503-512, 2006 | 169 | 2006 |
| A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer F Fang, C Balch, J Schilder, T Breen, S Zhang, C Shen, L Li, ... Cancer 116 (17), 4043-4053, 2010 | 158 | 2010 |
| Association of polymorphisms of angiogenesis genes with breast cancer BP Schneider, M Radovich, GW Sledge, JD Robarge, L Li, AM Storniolo, ... Breast cancer research and treatment 111 (1), 157-163, 2008 | 153 | 2008 |
| Prognostic DNA methylation biomarkers in ovarian cancer SH Wei, C Balch, HH Paik, YS Kim, RL Baldwin, S Liyanarachchi, L Li, ... Clinical Cancer Research 12 (9), 2788-2794, 2006 | 151 | 2006 |
| Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients S Borges, Z Desta, Y Jin, A Faouzi, JD Robarge, S Philip, A Nguyen, ... The Journal of Clinical Pharmacology 50 (4), 450-458, 2010 | 122 | 2010 |
| Patterns and severity of vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia EM Lavoie Smith, L Li, CW Chiang, K Thomas, RJ Hutchinson, EM Wells, ... Journal of the Peripheral Nervous System 20 (1), 37-46, 2015 | 112 | 2015 |
| Variability of heart rate correction methods for the QT interval M Desai, L Li, Z Desta, M Malik, D Flockhart British journal of clinical pharmacology 55 (6), 511-517, 2003 | 110 | 2003 |
| Loss of 14-3-3σ in prostate cancer and its precursors L Cheng, CX Pan, JT Zhang, S Zhang, MS Kinch, L Li, LA Baldridge, ... Clinical Cancer Research 10 (9), 3064-3068, 2004 | 105 | 2004 |
| Association between the CYP3A5 genotype and blood pressure H Ho, A Pinto, SD Hall, DA Flockhart, L Li, TC Skaar, P Cadman, ... Hypertension 45 (2), 294-298, 2005 | 103 | 2005 |
| Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions JD Duke, X Han, Z Wang, A Subhadarshini, SD Karnik, X Li, SD Hall, ... PLoS Comput Biol 8 (8), e1002614, 2012 | 101 | 2012 |
